Stocks
Fate Therapeutics (FATE) EBITDA US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | -94.2 | -125.0 | -211.1 | -294.6 | -172.2 | -178.2 | ||
| Changes by years, y/y, % | +45% | +33% | +69% | +40% | -42% | +21.6% | |||
Fate Therapeutics. EBITDA US GAAP, bln rub
Fate Therapeutics. EBITDA US GAAP, changes, %
Fate Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Fate Therapeutics (FATE) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA, bln rub | ? | -46.5 | -39.2 | -46.2 | -40.4 | -52.4 | -178.2 | |
| Changes by years, y/y, % | -44% | -39% | +90% | -31% | +13% | |||
| Changes by quarters, q/q, % | -20% | -16% | +18% | -13% | +30% | |||
